Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Clinical evidence

upLIFT

62 evidence topics · 14 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using glucose infusion rate reduction of at least 50% as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary
  • Design: upLIFT is a single-arm, open-label trial of 16 participants with no concurrent comparator, so the responder proportion is judged against a prespecified threshold (lower bound of the 95% confidence interval above 30%). The source documents word the threshold as “must exceed 30%” and as “must be ≥30%”.
  • Status of the data: the results are preliminary and come from company press releases and SEC filings; no publication, congress presentation, or registry results exist. At the 13 November 2026 evaluation, 3 participants remained in the pivotal period, and the final responder proportion and its confidence interval may differ.
  • Applicability: participants are adults who require IV glucose or parenteral nutrition despite standard-of-care therapies, with the primary endpoint measured in a hospital setting, and receive ersodetug as an add-on; the results describe the most severe presentation. Results by tumor type (insulinoma or non-islet cell tumor) and patient-reported quality of life have not been reported.
  • One participant with stage 4 metastatic colon cancer withdrew to hospice and was counted as a non-responder; outcomes in participants with poor performance status are therefore represented by a single case.
  • Registry records lag the company: ClinicalTrials.gov still lists the trial as recruiting, while the company reports enrollment complete.